"The U.S. Food and Drug Administration today expanded the approved use of Stivarga (regorafenib) to treat patients with advanced gastrointestinal stromal tumors (GIST) that cannot be surgically removed and no longer respond to other FDA-approved t"...
Instruct patients to inform their physician or healthcare provider if they:
- are pregnant or breast feeding.
- are sensitive to iodine, an iodine-containing contrast agent or other products that contain iodine.
- are sensitive to Potassium Iodide Oral Solution, or Lugol's Solution.
- have reduced renal function.
Instruct patients to increase their level of hydration prior to receiving AdreView (iobenguane i 123 injection for intravenous use) and to void frequently for the first 48 hours following AdreView (iobenguane i 123 injection for intravenous use) administration.
Last reviewed on RxList: 10/2/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional AdreView Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.